We are live on
!
Find out more
TC
Truvestments Capital Portfolio holdings
AUM
$554M
1-Year Est. Return
32.49%
This Fund
S&P 500
This Quarter
Est. Return
+7.39%
1 Year Est. Return
+32.49%
3 Year Est. Return
+86.71%
5 Year Est. Return
+90.42%
10 Year Est. Return
–
AUM
$144M
AUM Growth
-$9.15M
(-6%)
Cap. Flow
-$18.1M
Cap. Flow
% of AUM
-12.5%
Top 10 Holdings %
Top 10 Hldgs %
26.79%
Holding
704
New
1
Increased
73
Reduced
49
Closed
564
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$269K |
| 2 |
Vanguard FTSE Developed Markets ETF
VEA
|
+$197K |
| 3 |
Altria Group
MO
|
+$144K |
| 4 |
MPT
Medical Properties Trust
MPT
|
+$127K |
| 5 |
ExxonMobil
XOM
|
+$117K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$582K |
| 2 |
Marathon Petroleum
MPC
|
+$200K |
| 3 |
AerCap
AER
|
+$196K |
| 4 |
XPO
XPO
|
+$195K |
| 5 |
Campbell Soup
CPB
|
+$186K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 16.31% |
| 2 | Healthcare | 10.05% |
| 3 | Consumer Staples | 8.95% |
| 4 | Communication Services | 7.78% |
| 5 | Industrials | 7.57% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Vanguard Growth ETF
VUG
$216B
| $6.7M | 4.64% |
220,662
+582
| +0.3% | +$16.8K |
|
2
Apple
AAPL
$4.89T
| $5.76M | 3.99% |
78,420
-2,352
| -3% | -$151K |
|
3
Microsoft
MSFT
$2.84T
| $3.85M | 2.67% |
24,432
+12
| +0% | +$1.76K |
|
4
Vanguard Value ETF
VTV
$189B
| $3.76M | 2.6% |
31,378
-124
| -0.4% | -$14.3K |
|
5
Johnson & Johnson
JNJ
$635B
| $3.25M | 2.25% |
22,270
-30
| -0.1% | -$4.07K |
|
6
Procter & Gamble
PG
$343B
| $3.18M | 2.2% |
25,430
+125
| +0.5% | +$15.3K |
|
7
Intel
INTC
$466B
| $3.16M | 2.19% |
52,872
+1,080
| +2% | +$60.4K |
|
8
Amazon
AMZN
$2.5T
| $3.04M | 2.11% |
32,920
+400
| +1% | +$35.4K |
|
9
Vanguard Dividend Appreciation ETF
VIG
$111B
| $3.01M | 2.08% |
24,116
-550
| -2% | -$66.5K |
|
10
NextEra Energy
NEE
$187B
| $2.98M | 2.06% |
49,256
+748
| +2% | +$43.7K |
|
11
Vanguard Small-Cap ETF
VB
$79.5B
| $2.81M | 1.95% |
16,959
-198
| -1% | -$31.5K |
|
12
AT&T
T
$165B
| $2.79M | 1.93% |
94,610
+2,596
| +3% | +$75K |
|
13
Vanguard Mid-Cap ETF
VO
$106B
| $2.65M | 1.83% |
59,460
-2,000
| -3% | -$85.9K |
|
14
CVS Health
CVS
$137B
| $2.58M | 1.79% |
34,748
-1,355
| -4% | -$95.1K |
|
15
Qualcomm
QCOM
$176B
| $2.41M | 1.67% |
27,352
+283
| +1% | +$23.7K |
|
16
WisdomTree US MidCap Dividend Fund
DON
$4.03B
| $2.18M | 1.51% |
57,300
| – | – |
|
17
Alphabet (Google) Class C
GOOG
$3.9T
| $2.15M | 1.49% |
32,240
+760
| +2% | +$49K |
|
18
3M
MMM
$89B
| $2.07M | 1.43% |
14,035
+37
| +0.3% | +$5.18K |
|
19
Omega Healthcare
OHI
$15.4B
| $2M | 1.39% |
47,254
-522
| -1% | -$22.1K |
|
20
WisdomTree US SmallCap Dividend Fund
DES
$2.19B
| $1.99M | 1.38% |
69,454
-100
| -0.1% | -$2.79K |
|
21
Meta Platforms (Facebook)
META
$1.51T
| $1.86M | 1.29% |
9,047
-33
| -0.4% | -$6.39K |
|
22
Invesco BuyBack Achievers ETF
PKW
$1.69B
| $1.85M | 1.28% |
26,845
-910
| -3% | -$59.9K |
|
23
AbbVie
ABBV
$458B
| $1.83M | 1.27% |
20,718
+1,152
| +6% | +$95.6K |
|
24
Iron Mountain
IRM
$38.2B
| $1.76M | 1.22% |
55,147
+2,329
| +4% | +$76.4K |
|
25
Cisco
CSCO
$450B
| $1.68M | 1.16% |
35,032
+492
| +1% | +$22.9K |
|
Similar funds
SIM
FFA
CCA
HWM
TPA
TAWM
CA
SIAP
Truvestments Capital's Q4 2019 Portfolio in Review
As of Q4 2019, Truvestments Capital held 704 positions worth $144M, down 6% from $154M the previous quarter. Its ten largest holdings account for 27% of the portfolio.
Truvestments Capital withdrew a net $18.1M in Q4 2019, closing 564 positions and reducing 49 holdings. Its most notable exit was Celgene Corp, an estimated $582K position sold in full.
By sector, the portfolio is most concentrated in Technology at 16% of assets, up from 15% a quarter earlier, followed by Healthcare and Consumer Staples.
Against the trend, Truvestments Capital opened a new position in Vanguard FTSE Developed Markets ETF worth $204K.
- Truvestments Capital's largest Q4 2019 buy was Vanguard FTSE Developed Markets ETF: 4,627 shares worth $204K.
- Truvestments Capital added most to Bristol-Myers Squibb in Q4 2019, an estimated $269K increase.
- Truvestments Capital's biggest Q4 2019 reduction was Apple, cutting an estimated $151K.
- Truvestments Capital fully exited Celgene Corp in Q4 2019, selling an estimated $582K.
- Truvestments Capital's ten largest holdings make up 27% of its $144M portfolio in Q4 2019.
- Truvestments Capital opened 1 new position and closed 564 in Q4 2019.
- Truvestments Capital's portfolio value fell 6% quarter-over-quarter to $144M.
Based on Truvestments Capital's 13F filing for Q4 2019, filed 29 Jan 2020.